Sarclisa receives EMA approval for multiple myeloma, Sanofi develops new treatments, and Trump-era tariffs benefit AI stocks.
2 reports, 2 independent
Updated Aug 26
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sarclisa receives EMA approval for multiple myeloma, Sanofi develops new treatments, and Trump-era tariffs benefit AI stocks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA grants approval for Sarclisa in multiple myeloma.1 source
Sarclisa and Sanofi advance multiple myeloma treatments, while AI stocks benefit from Trump-era tariffs.1 source
Keep exploring
The entities involved
-
Sanofi
company in Milan, Italy
Nothing else this week.
Coverage
Newest first; wire copies grouped- fool.com
- Insider MonkeySanofi (SNY)’s Sarclisa Gets EMA Nod for Multiple Myeloma We recently published 11 Best Cancer Stocks to Buy Right Now. Sanofi is placed eighth among them. Sanofi (NASDAQ:SNY) is a global biopharmace